ReviewCancers2023
Telemedicine in Care of Sarcoma Patients beyond the COVID-19 Pandemic: Challenges and Opportunities.
Review in Cancers, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Establishing a Musculoskeletal Oncology Unit: Teamwork Triumphs!!!Indian journal of surgical oncology · 2026Article
- PICO-based assessment and categorization of evidence for digital health interventions: an inductive framework development.Frontiers in digital health · 2026Review
- Review
- How Musculoskeletal Tumor Management Changed During the COVID-19 Pandemic: Data from a Nationwide Questionnaire Survey of Hospitals Specializing in Musculoskeletal Tumors in Japan.Current oncology (Toronto, Ont.) · 2025Article
- Diagnostic Delay in Soft Tissue Sarcomas: A Review.Cancers · 2025Review
- Barriers and facilitators of using tele-oncology in cancer care: a scoping review.BMC health services research · 2025Article
- The Impact of the COVID-19 Pandemic on Work-Life Integration of Physician Assistants in Oncology.Journal of the advanced practitioner in oncology · 2025Article
- Utility of artificial intelligence in a binary classification of soft tissue tumors.Journal of pathology informatics · 2024Article
- The potential of virtual healthcare technologies to reduce healthcare services' carbon footprint.Frontiers in public health · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundThe COVID-19 pandemic has created a challenging environment for sarcoma patients. Most oncology societies published guidelines or recommendations prioritizing sarcoma patients and established telehealth as an efficient method of approaching them. The aim of this review is the assessment of current evidence regarding the utilization of telemedicine in diagnosis, treatment modalities, telerehabilitation and satisfaction among sarcoma patients and healthcare providers (HP).
methodsThis systematic review was carried out using the databases PubMed and Ovid MEDLINE according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA).
resultsThe application of telemedicine to the management of sarcoma has yielded improved clinical and psychological outcomes. Specifically, significant progress has been demonstrated in the areas of tele-oncology and telerehabilitation during the last decade, and the COVID-19 outbreak has accelerated this transition toward them. Telehealth has been proven efficient in a wide spectrum of applications from consultations on physical therapy and psychological support to virtual care symptom management. Both HP and patients reported satisfaction with telehealth services at levels comparable to in-person visits.
conclusionsTelehealth has already unveiled many opportunities in tailoring individualized care, and its role in the management of sarcoma patients has been established in the post-COVID-19 era, as well.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.